ClinicalTrials.gg
CompletedNCT00159835IDEALUpdated Apr 22, 2015

Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD

A Phase 4 interventional study of atorvastatin and simvastatin in Cardiovascular Diseases, sponsored by Pfizer. Completed at 194 sites in 6 countries. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2015-04-22.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8,600
Allocation
Randomized
Ages
Up to 80 Years
Sex
All
01

Study summary

To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.

02

Conditions studied

  • Cardiovascular Diseases
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 8,600 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous myocardial infarction

Exclusion criteria

Exclusion Criteria:

  • Women who are breast feeding or are pregnant
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,600 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Time to of a major coronary event: 1) non-fatal acute myocardial infarction 2) coronary death 3) resuscitated cardiac arrest

Secondary outcomes

  1. 1) Time to any CHD event, 2) Time to Hospitalization with primary diagnosis of CHF, 3) Time to Cerbrovascular Event, 4) Time to PAD, 5) Time to any CV event and 6) All Cause Mortality

07

Study locations

194 sites
  • Pfizer Investigational Site
    Arhus C, DK-8000, Denmark
  • Pfizer Investigational Site
    Copenhagen, 2100, Denmark
  • Pfizer Investigational Site
    Esbjerg, 6700, Denmark
  • Pfizer Investigational Site
    Fredericia, 7000, Denmark
  • Pfizer Investigational Site
    Frederiksberg, 2000, Denmark
  • Pfizer Investigational Site
    Frederikssund, 3600, Denmark
  • Pfizer Investigational Site
    Grena, 8500, Denmark
  • Pfizer Investigational Site
    Helsingoer, 3000, Denmark
  • Pfizer Investigational Site
    Hjorring, 9800, Denmark
  • Pfizer Investigational Site
    Holbak, 4300, Denmark
  • Pfizer Investigational Site
    Holstebro, 7500, Denmark
  • Pfizer Investigational Site
    Hvidovre, 2650, Denmark
  • Pfizer Investigational Site
    Kabenhavn S, 2300, Denmark
  • Pfizer Investigational Site
    Kalundborg, 4400, Denmark
  • Pfizer Investigational Site
    Kobenhavn K, 1256, Denmark
  • Pfizer Investigational Site
    Kobenhavn Nv, 2400, Denmark
  • Pfizer Investigational Site
    Koge, 4600, Denmark
  • Pfizer Investigational Site
    København NV, 2400, Denmark
  • Pfizer Investigational Site
    Middelfart, 5500, Denmark
  • Pfizer Investigational Site
    Naestved, 4700, Denmark
  • Pfizer Investigational Site
    Nykobing F, 4800, Denmark
  • Pfizer Investigational Site
    Odder, 8300, Denmark
  • Pfizer Investigational Site
    Randers, 8900, Denmark
  • Pfizer Investigational Site
    Roskilde, 4000, Denmark
  • Pfizer Investigational Site
    Silkeborg, 8600, Denmark
  • Pfizer Investigational Site
    Skive, 7800, Denmark
  • Pfizer Investigational Site
    Slagelse, 4200, Denmark
  • Pfizer Investigational Site
    Svendborg, 5700, Denmark
  • Pfizer Investigational Site
    Heinola, 18100, Finland
  • Pfizer Investigational Site
    Helsinki, 00029, Finland
  • Pfizer Investigational Site
    Helsinki, 00100, Finland
  • Pfizer Investigational Site
    Joensuu, 80210, Finland
  • Pfizer Investigational Site
    Jyvaskyla, 40100, Finland
  • Pfizer Investigational Site
    Kerava, 04200, Finland
  • Pfizer Investigational Site
    Kuopio, 70210, Finland
  • Pfizer Investigational Site
    Lahti, 15110, Finland
  • Pfizer Investigational Site
    Lappeenranta, 53130, Finland
  • Pfizer Investigational Site
    Lohja, 08200, Finland
  • Pfizer Investigational Site
    Mikkeli, 50100, Finland
  • Pfizer Investigational Site
    Rauma, 26100, Finland
  • Pfizer Investigational Site
    Salo, 24130, Finland
  • Pfizer Investigational Site
    Siaraalamaki, 45750, Finland
  • Pfizer Investigational Site
    Tammisaari, 10600, Finland
  • Pfizer Investigational Site
    Tampere, 33520, Finland
  • Pfizer Investigational Site
    Vantaa, 01400, Finland
  • Pfizer Investigational Site
    Reykjavik, 101, Iceland
  • Pfizer Investigational Site
    Reykjavik, 108, Iceland
  • Pfizer Investigational Site
    's-Hertogenbosch, 5211 NL, Netherlands
  • Pfizer Investigational Site
    Alkmaar, 1815 JD, Netherlands
  • Pfizer Investigational Site
    Amsterdam, 1061 AE, Netherlands
  • Pfizer Investigational Site
    Assen, 9401 RK, Netherlands
  • Pfizer Investigational Site
    Breda, 4818 CK, Netherlands
  • Pfizer Investigational Site
    Capelle Aan Den Ijssel, 2906 ZC, Netherlands
  • Pfizer Investigational Site
    Delft, 2625 AD, Netherlands
  • Pfizer Investigational Site
    Deventer, 7415 CM, Netherlands
  • Pfizer Investigational Site
    EDE, 6716 RP, Netherlands
  • Pfizer Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • Pfizer Investigational Site
    Enschede, 7511 JX, Netherlands
  • Pfizer Investigational Site
    Goes, 4462 RA, Netherlands
  • Pfizer Investigational Site
    Groningen, 9721 SW, Netherlands
  • Pfizer Investigational Site
    Hoorn, 1624 GM, Netherlands
  • Pfizer Investigational Site
    Nijmegen, 6532 SZ, Netherlands
  • Pfizer Investigational Site
    Oss, NL-5342 BT, Netherlands
  • Pfizer Investigational Site
    Rotterdam, 3045 PM, Netherlands
  • Pfizer Investigational Site
    Tilburg, 5022 GC, Netherlands
  • Pfizer Investigational Site
    Tilurg, 5022 GC, Netherlands
  • Pfizer Investigational Site
    Utrecht, NL-3508-TG, Netherlands
  • Pfizer Investigational Site
    Weert, 6001 BE, Netherlands
  • Pfizer Investigational Site
    Zwijndrecht, 3331 LZ, Netherlands
  • Pfizer Investigational Site
    Zwolle, 8011 JW, Netherlands
  • Pfizer Investigational Site
    Alesund, 6002, Norway
  • Pfizer Investigational Site
    Alesund, 6026, Norway
  • Pfizer Investigational Site
    Bergen, 5008, Norway
  • Pfizer Investigational Site
    Bergen, 5009, Norway
  • Pfizer Investigational Site
    Bergen, 5012, Norway
  • Pfizer Investigational Site
    Bergen, 5015, Norway
  • Pfizer Investigational Site
    Bergen, 5021, Norway
  • Pfizer Investigational Site
    Bodo, 8092, Norway
  • Pfizer Investigational Site
    Flekkefjord, 4400, Norway
  • Pfizer Investigational Site
    Forde, 6807, Norway
  • Pfizer Investigational Site
    Hammerfest, 9613, Norway
  • Pfizer Investigational Site
    Haugesund, 5500, Norway
  • Pfizer Investigational Site
    Hobøl, 1827, Norway
  • Pfizer Investigational Site
    Jessheim, 2050, Norway
  • Pfizer Investigational Site
    Karasjok, 9735, Norway
  • Pfizer Investigational Site
    Kongsberg, 3600, Norway
  • Pfizer Investigational Site
    Kongsvinger, 2226, Norway
  • Pfizer Investigational Site
    Kragero, 3770, Norway
  • Pfizer Investigational Site
    Kristiansand, 4612, Norway
  • Pfizer Investigational Site
    Kristiansund N, 6508, Norway
  • Pfizer Investigational Site
    Larvik, 3257, Norway
  • Pfizer Investigational Site
    Levanger, 7600, Norway
  • Pfizer Investigational Site
    Lillestom, 2000, Norway
  • Pfizer Investigational Site
    Lorenskog, 1478, Norway
  • Pfizer Investigational Site
    Mo I Rana, 8607, Norway
  • Pfizer Investigational Site
    Molde, 6407, Norway
  • Pfizer Investigational Site
    Molde, 6415, Norway
  • Pfizer Investigational Site
    Mosjøen, 8656, Norway
  • Pfizer Investigational Site
    Moss, 1502, Norway
  • Pfizer Investigational Site
    Mysen, 1850, Norway

Showing the first 100 of 194 sites across 6 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437. Erratum In: JAMA. 2005 Dec 28;294(24):3092. PubMed 16287954 ↗
  • Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0. PubMed 28573499 ↗
  • Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648. PubMed 28214794 ↗
  • Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30. PubMed 27513651 ↗
  • Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR, Hovingh GK; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015 Mar;101(5):356-62. doi: 10.1136/heartjnl-2014-306906. Epub 2015 Jan 16. PubMed 25595417 ↗
  • Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14. PubMed 23674398 ↗
  • Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524. PubMed 22576673 ↗
  • Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3. PubMed 20130232 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 1999 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Feb 1999
Completion
Mar 2005
Last update
Apr 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Apr 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00159835
Lead sponsor
Pfizer
First posted
Sep 12, 2005
Start date
Feb 1999
Completion
Mar 2005
Last update
Apr 22, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Simvastatin

Start the discussion